NORTHBROOK, Ill.--(BUSINESS WIRE)--Marathon Pharmaceuticals today announced the opening of the Marathon Bioscience Center, located in Chicago’s River North district. The facility houses the company’s research, clinical and regulatory staff who work to develop and register new treatments for rare diseases.
Under the leadership of Dr. Timothy Cunniff, executive vice president for research and development, the Marathon Bioscience Center is developing new therapies for cancer, central nervous system diseases, endocrine deficiencies, gastrointestinal diseases and movement disorders. The majority of treatments in the company’s pipeline are focused on patients with rare diseases whose medical needs are unmet.
“Marathon is developing new medications for patients who currently have no treatment options. The rapid growth of our pipeline is creating high-tech bioscience jobs in Chicago,” said Jeffrey S. Aronin, Marathon Pharmaceuticals chairman and chief executive officer. “We made a strategic decision to expand into Chicago, which has a growing bioscience community and attracts top talent because of its outstanding universities and medical centers.”
The Chicago facility, located at 321 N. Clark Street, puts the Marathon research and development team close to MATTER, the downtown hub for biotech startups expected to open in late 2014. Aronin, who leads the bioscience committee of ChicagoNEXT, an affiliate of World Business Chicago, is co-chair of MATTER.
Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases and makes small volume, hard-to-manufacture medications available to people who need them. Marathon is focused on providing medicine to patients who currently have no treatment options. The company manufactures prescription medications and is developing a pipeline of treatments for rare cancers and neurological disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago and New Jersey. For more information visit www.marathonpharma.com.